Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Maeurer

Showing results (21-30 of 206) with videos related to

Pageof 21
Sort By:
The Lancet. Infectious Diseases|March 28, 2014
Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccinesAlimuddin I Zumla, Marco Schito, Markus Maeurer
JAMA Surgery|March 24, 2016
The Ethical Dilemma of Compensating Living Kidney Donors: Alignment Between Science, Legislation, and Ethical Perception in Society?Marco Del Chiaro, Elena Rangelova, Markus Maeurer
BMC Medicine|June 16, 2016
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisAlimuddin Zumla, Martin Rao, Ernest Dodoo, et al.
Lancet (London, England)|August 9, 2011
Xpert MTB/RIF test for tuberculosisGiovanni Ferrara, Justin O'Grady, Alimuddin Zumla, et al.
Frontiers in Oncology|October 5, 2018
KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic CancerQingda Meng, Davide Valentini, Martin Rao, et al.
The Lancet. Infectious Diseases|March 28, 2013
Zero deaths from tuberculosis: progress, reality, and hopeAlimuddin Zumla, Peter Kim, Markus Maeurer, et al.
The Journal of Infectious Diseases|March 30, 2012
Adjunct immunotherapies for tuberculosisMichael Uhlin, Jan Andersson, Alimuddin Zumla, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 5, 2018
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosisMartin Rao, Davide Valentini, Alimuddin Zumla, et al.
Frontiers in Microbiology|May 29, 2019
Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed TherapiesMartin Rao, Ernest Dodoo, Alimuddin Zumla, et al.
The Lancet. Respiratory Medicine|March 3, 2019
Towards optimal treatment for latent Mycobacterium tuberculosis infectionIbrahim Abubakar, Jeremiah Chakaya, Markus Maeurer, et al.
Pageof 21

Showing results (21-30 of 206) with videos related to

Sort By:
Pageof 21
The Lancet. Infectious Diseases|March 28, 2014
Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccinesAlimuddin I Zumla, Marco Schito, Markus Maeurer
JAMA Surgery|March 24, 2016
The Ethical Dilemma of Compensating Living Kidney Donors: Alignment Between Science, Legislation, and Ethical Perception in Society?Marco Del Chiaro, Elena Rangelova, Markus Maeurer
BMC Medicine|June 16, 2016
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisAlimuddin Zumla, Martin Rao, Ernest Dodoo, et al.
Lancet (London, England)|August 9, 2011
Xpert MTB/RIF test for tuberculosisGiovanni Ferrara, Justin O'Grady, Alimuddin Zumla, et al.
Frontiers in Oncology|October 5, 2018
KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic CancerQingda Meng, Davide Valentini, Martin Rao, et al.
The Lancet. Infectious Diseases|March 28, 2013
Zero deaths from tuberculosis: progress, reality, and hopeAlimuddin Zumla, Peter Kim, Markus Maeurer, et al.
The Journal of Infectious Diseases|March 30, 2012
Adjunct immunotherapies for tuberculosisMichael Uhlin, Jan Andersson, Alimuddin Zumla, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 5, 2018
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosisMartin Rao, Davide Valentini, Alimuddin Zumla, et al.
Frontiers in Microbiology|May 29, 2019
Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed TherapiesMartin Rao, Ernest Dodoo, Alimuddin Zumla, et al.
The Lancet. Respiratory Medicine|March 3, 2019
Towards optimal treatment for latent Mycobacterium tuberculosis infectionIbrahim Abubakar, Jeremiah Chakaya, Markus Maeurer, et al.
Pageof 21